Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Targeted therapy for nonsmall cell lung cancer (NSCLC) frequently fails due to acquired drug resistance and genetic mutations.
• These mutations drive aerobic glycolysis, leading to lactate accumulation that suppresses the anti-tumor immune response.
• Elevated lactate levels create an immunosuppressive tumor microenvironment, hindering effective cancer treatment.

Purpose of the Study:

• To review the role of lactate expression in NSCLC.
• To explore the potential of lactate oxidase (LOX) in managing lactate levels.
• To discuss the impact of lactate depletion on immune cell populations and therapeutic strategies.

Main Methods:

• Literature review of studies on lactate metabolism in NSCLC.
• Analysis of the function of lactate oxidase (LOX) in lactate turnover.
• Examination of the relationship between lactate levels and immune cell infiltration.

Main Results:

• Lactate accumulation is a hallmark of NSCLC, contributing to therapeutic resistance and immune suppression.
• Enzymatic reduction of lactate shows promise in modulating the tumor immune microenvironment.
• Lactate depletion may enhance the efficacy of existing and novel cancer therapies.

Conclusions:

• The lactate-rich nature of NSCLC presents a targetable vulnerability.
• Lactate oxidase (LOX) offers a potential therapeutic strategy for NSCLC treatment.
• Integrating lactate-lowering approaches with conventional therapies could improve patient outcomes.